In summary, our present findings elucidated the importance of SRC-3 in proteasome-inhibitor-induced drug resistance in myeloma cells, and uncovered its interaction with the histone methyltransferase NSD2. The gene discussed is PRDM9; the disease is plasma cell myeloma.